Olmesartan, Amlodipina E Idroclorotiazide Eg

Olmesartan medoxil, the active ingredient in Olmesartan, Amlodipina E Idroclorotiazide Eg, is an angiotensin II receptor blocker presented as a tablet for oral use. It helps lower blood pressure in adults with hypertension. The product also contains amlodipine besilate, a calcium‑channel blocker, and hydrochlorothiazide, a thiazide diuretic, providing a triple mechanism to control blood pressure.

GNH USA supplies Olmesartan, Amlodipina E Idroclorotiazide Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan, amlodipine and hydrochlorothiazide combination is used in the management of hypertension, targeting the renin‑angiotensin system, calcium channels, and diuretic pathways. - Hypertension: reduces systolic and diastolic blood pressure in adults. - Resistant hypertension: provides additive effect when monotherapy is insufficient. - Cardiovascular risk reduction: helps lower the risk of stroke and myocardial infarction in high‑risk patients.

Common Side Effects: - Dizziness: mild to moderate light‑headedness, especially after standing. - Peripheral edema: swelling of the ankles or feet. - Headache: transient tension‑type headache. - Flushing: warm sensation with reddening of the skin. - Fatigue: general tiredness. - Increased urination: due to diuretic effect.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue or throat. - Severe hypotension: marked drop in blood pressure causing faintness. - Renal impairment: sudden decrease in kidney function. - Electrolyte disturbances: hyperkalemia, hyponatremia or other imbalances. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Anaphylactic reaction: severe allergic response requiring emergency care.

Precautions should be taken when initiating or adjusting therapy with this combination. - Monitor blood pressure: check regularly after starting or changing dose. - Assess renal function: evaluate serum creatinine and electrolytes periodically. - Review hepatic status: use with caution in patients with liver disease. - Pregnancy: avoid use due to potential fetal toxicity. - Concomitant potassium‑sparing agents: risk of hyperkalemia; monitor serum potassium. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Potential drug interactions must be considered. Major Interactions (Avoid): - ACE inhibitors or other ARBs: additive risk of renal dysfunction. - Potassium‑sparing diuretics or supplements: may cause hyperkalemia. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase amlodipine exposure. Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Lithium: increased lithium concentrations, risk of toxicity.